Decision Making in a World of Comparative Effectiveness Research A Practical Guide /
In the past decade there has been a worldwide evolution in evidence-based medicine that focuses on real-world Comparative Effectiveness Research (CER) to compare the effects of one medical treatment versus another in real world settings. While most of this burgeoning literature has focused on resear...
| Corporate Author: | |
|---|---|
| Other Authors: | , |
| Language: | English |
| Published: |
Singapore :
Springer Singapore : Imprint: Adis,
2017.
|
| Edition: | 1st ed. 2017. |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/978-981-10-3262-2 |
Table of Contents:
- I. Introduction
- 1. Introducing Decision Making in a World of Comparative Effectiveness Research
- 2. Perspectives on Decision Making in a World of Comparative Effectiveness: Views from Diverse Constituencies
- II. The Future of CER for Evidence Developers: Perspectives from Pharmaceutical Decision Makers
- 3. Perspectives on the Use of CER by Life Sciences Executives: An Interview with Mike Bonney
- 4. Perspectives on the Use of CER by Life Sciences Executives: An Interview with a Senior Executive at an International Life Science Company
- 5. CER: A Pharmaceutical Industry Perspective on Outlook, Dilemmas, and Controversies
- 6. Impact of Comparative Effectiveness Research on Drug Development Strategy and Innovation
- 7. Pricing of Pharmaceuticals: Current Trends and Outlook, and the Role of CER
- III. Evolving Stakeholder Considerations: Patients, Physicians, Regulators and Payers
- 8. Are Real-World Data and Evidence Good Enough to Inform Healthcare and Health Policy Decision Making?
- 9. Translating CER Evidence to Real-World Decision-Making: Some Practical Considerations
- 10. Decision Making by Public Payers
- 11. Patient and Stakeholder Engagement in Designing Pragmatic Clinical Trials
- 12. Policy Considerations: Ex-U.S. Payers and Regulators
- 13. Perspectives on the Common Drug Review (CDR) Process at the Canadian Agency for Drugs and Technologies in Health (CADTH)
- 14. Evaluating Non-Pharmaceutical Technologies at the Canadian Agency for Drugs and Technologies in Health (CADTH)
- 15. Challenges and Opportunities in the Dissemination of CER Information to Physicians and Payers: A Legal Perspective
- 16. Legal Considerations in a World of CER
- IV. Emerging Challenges, Methods and Applications of CER: Real-world and Big Data
- 17. Application of CER to Promote Adherence to Clinical Practice Guidelines
- 18. Challenges in Developing and Assessing CER for Medical Technology
- 19. Evidence Generation Using Big Data: Challenges and Opportunities
- 20. Indirect Comparisons Using Clinical Trial Data: 5 Years Later
- 21. Decision-Making with Machine Learning in Our Modern, Data-Rich Healthcare Industry.